GA-K4

General Information


DRACP ID  DRACP00410

Peptide Name   GA-K4

Sequence  FLKWLFKWAKK

Sequence Length  11

UniProt ID  Not available

PubChem CID  Not available

Origin  Brevinin-1EMa

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A498 Renal cell carcinoma Carcinoma IC50=21.48 µM MTT assay 72 h 1
A549 Lung adenocarcinoma Carcinoma IC50=14.53 µM MTT assay 72 h 1
HCT 116 Colon carcinoma Carcinoma IC50=14.8 µM MTT assay 72 h 1
MKN45 Gastric adenocarcinoma Carcinoma IC50=22.51 µM MTT assay 72 h 1
PC-3 Prostate carcinoma Carcinoma IC50=29.10 µM MTT assay 72 h 1
SK-MEL-2 Melanoma Carcinoma IC50=22.25 µM MTT assay 72 h 1
SK-N-DZ Neuroblastoma Blastoma IC50=12.55 µM MTT assay 72 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00410

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C79H115N17O12

Absent amino acids  CDEGHIMNPQRSTVY

Common amino acids  K

Mass  167344

Pl  11.28

Basic residues  4

Acidic residues  0

Hydrophobic residues  7

Net charge  4

Boman Index  7

Hydrophobicity  -21.82

Aliphatic Index  80

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  11000

Absorbance 280nm  1100

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22644847

Title  Anticancer activity of undecapeptide analogues derived from antimicrobial peptide, brevinin-1EMa

Doi 10.1007/s12272-012-0505-0

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.